Hero Image
18 October 2018
Berlin, Germany
RegMed Forum 2018 - Smart Medical Devices

RegMed Forum 2018: Smart Medical Devices

The Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and Berlin Partner are jointly organising the RegMed Forum 2018 on October, 18th 2018 in Berlin, Germany. This year, the international conference will focus on smart medical devices.

Together, stakeholders from industry, clinics and academia will explore the following topics:

  • Biologised medical devices
  • Intelligent implants
  • Medical Device Regulation

Confirmed speakers (as of August)

  • Jill Helms, Stanford University, USA
  • Andrew Carr, Oxford, UK
  • Elke Lieb, Heraeus Holding GmbH, Wehrheim, Germany
  • Abhay Pandit, NUI Galway, Ireland
  • Viola Vogel, ETH Zürich, Swiss
  • Thomas Grupp, Aesculap AG, Tuttlingen, Germany
  • Thomas Müller, Federal Ministry of Health, Berlin, Germany
  • Beat Lechmann, Johnson & Johnson Medical Devices, Zuchwil, Swiss
  • Georg N. Duda, Julius Wolff Institute, Berlin, Germany
  • Tobias Winkler, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
  • Max Heiland, Charité, Berlin, Germany
  • Dominik Karch, Berlin Heart GmbH, Berlin, Gemany
  • Katarina Braune, Charité, Berlin, Germany
  • Frank Witte, botiss GmbH, Berlin, Germany
  • Christian Dierks, Dierks+Company Rechtsanwaltsgesellschaft mbH, Berlin, Germany
  • Mohamed Abou-El-Enein, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
  • Philipp Damm, Julius Wolff Institute, Berlin, Germany
  • Mohit Chhaya, BellaSeno GmbH, Leipzig, Germany

What can you expect?

  • Conference program about latest trends in smart medical devices
  • Industry pitches and exhibition to present products, services and technologies from international and national enterprises

The RegMed Forum is an open access conference, participation is free of charge.

About the event

The “RegMed Forum 2018 – Smart Medical Devices” provides the opportunity to network with important actors along the value chain and supports transferring innovations from basic research into clinics and industry. In addition to a comprehensive scientific program with presentations from local research groups, international guests from academia and industry, there will be plenty of opportunities for industry and research groups to present their field of activities and to network in the industry exhibition.

About Berlin Brandenburg Center for Regenerative Medicine (BCRT)

The research landscape of Berlin/Brandenburg has developed into one of the most important international clusters for Regenerative Medicine. A major contribution to this development has been the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), which was established 12 years ago. The BCRT is an interdisciplinary clinical translational center jointly operated by Charité Universitaetsmedizin Berlin and Helmholtz-Zentrum Geesthacht (with its site in Teltow).

The BCRT’s focus lies on the concept of endogenous regeneration, which is realized by using cells, biomaterials, factors and the combination thereof, and addresses primarily diseases of the immune system, the musculoskeletal system and the cardiovascular system. First fruits of success with regard to the development and implementation of innovative therapies and products from BCRT are, e.g., virus-specific T-cell products for long-term protection against serious infections, which particularly affect patients with a weakened immune system. They are now evaluated in clinical studies on site. Following the concept of refined translation, i.e. iterative incorporation of (pre-)clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards a clinical evaluation. This includes new cell-based approaches for heart disease and muscle injuries as well as new polymer-based devices like cardiovascular implants and systems for soft tissue regeneration or drug release. Such approaches may give rise to an enormous worldwide commercial potential, as the commercialization of Regenerative Medicine has just begun.



This project is funded by resources from the federal state of Berlin and by the european fund for regional development from the investment bank of Berlin.

Gefördert aus Mitteln des Landes Berlin und des Europäischen Fonds für regionale Entwicklung durch die Investitionsbank Berlin.


Closed since 17 October 2018


Berlin, Germany

Organised by


Austria 1
Czech Republic 3
Estonia 1
Germany 118
Israel 1
Italy 1
Nigeria 1
Portugal 1
Ukraine 1
United Kingdom 2
Total 130


Company 59
University 40
R&D Institution 18
Association/Agency 1
Authority/Government 2
Other 10
Total 130